Further studies have demonstrated RAS-MAPK dependence as a hallmark of EML4-ALK rearranged NSCLC, with reactivation of the MAPK pathway associated with resistance to ALK inhibition [29]. Here, ALK is linked to non-small cell lung carcinoma.